Cencora entered an agreement with Kite (a Gilead company) to support distribution of Kite’s FDA-approved CAR T therapies Yescarta and Tecartus across the United States. The partnership targets expansion of access at authorized treatment centers, including health systems and community oncology practices. Cencora will leverage its specialty distribution infrastructure to reduce administrative burdens for providers as Kite scales its center network. The collaboration is designed to create a more streamlined experience for complex, individualized cell therapies, particularly around order management across multiple sites. The deal signals continued operational consolidation in the CAR T ecosystem, where logistics and therapy readiness have become as important as clinical performance for scaling patient access.